Changes in healthcare utilization and costs associated with sildenafil therapy for pulmonary arterial hypertension: A retrospective cohort study

Little is known concerning the degree to which initiation of sildenafil for pulmonary arterial hypertension (PAH) impacts patterns of healthcare utilization and costs. The cost of sildenafil therapy may be partially offset by reductions in other healthcare costs.